IpAuctions Inc. to Sell Medical Patent and Patent Application on Behalf of CyDex Pharmaceuticals, Inc.
Published April 4th, 2009
IpAuctions, Inc. (www.ipauctions.com) will auction one pharmaceutical patent and one patent application on behalf of specialty pharmaceutical company CyDex Pharmaceuticals, Inc. (www.cydexpharma.com) of Lenexa, Kansas, USA.
The patent application is for a novel taste-masking formulation which CyDex has developed. CyDex’s Captisol® (sulfobutyl ether β-cyclodextrin) has been combined with Sertraline (the selective serotonin reuptake inhibitor (SSRI) drug commercially sold as ZOLOFT™, the anti-anxiety drug manufactured by Pfizer Inc. of New York, New York, USA.) Key benefits of this formulation by CyDex are: the previously bitter taste of the drug is masked; no dilution of the medicine is required; and, as an oral concentrate, this formulation may be administered via multiple beverages – such as juice, soda, etc. – without precipitation.
The second medical patent to be auctioned by IpAuctions, Inc. on behalf of CyDex Pharmaceutical, Inc. is one for a formulation containing Propofol and Captisol. Propofol is a sedative hypnotic drug, and in this patented formulation, there is reduced incidence of pain upon injection. CyDex’s Captisol-enabled Propofol forms a “true aqueous solution and is not a suspension,” according to the U.S. Patent abstract.
Propofol is most commonly used as a short-acting intravenous sedative agent before the introduction of general anesthesia and during maintenance of general anesthesia. It often is used in veterinary procedures. Key benefits of CyDex’s Captisol-enabled Propofol are:
The solution is not an emulsion like the current forms of products using propofol; the solution is stable; there are no “lipid-loading” concerns (hyperlipidemia) for children and senior citizens with nutritional support issues; the solution contains no sulfites, thus reducing allergies (for example, egg allergies); this formulation is easy to sterilize and manufacture; and finally, the solution is freezable.
CyDex Pharmaceuticals, Inc. is selling the patent application for the Sertraline formulation and the patent for the Propofol formulation “because these two developments are outside of the corporation’s target markets,” explained Ralph S. Johnston, vice president of business development and marketing, CyDex Pharmaceuticals, Inc.
About CyDex Pharmaceuticals, Inc. CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol® technology. CyDex is developing its own pipeline of products using its enabling technology solutions and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. The company maintains patents in the U.S. and worldwide for its Captisol and cyclodextrin technologies, and a comprehensive FDA drug master file for client use. For additional information on business development opportunities, please contact Ralph Johnston at rjohnston@cydexpharma.com or 913-685-8850. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexpharma.com. To view the two medical patents to be auctioned in this sale, please visit www.ipAuctions.com.
About IpAuctions®, Inc. (www.ipAuctions.com) is the leading online auction firm specializing in the sale of intellectual property assets. The firm has a proprietary database of over 8,500 IP attorneys, corporate and private buyers, and venture capitalists, who wish to maximize their IP assets. IpAuctions, Inc. is a member of the National Auctioneers Association and the ABI. The company is based in Reno, Nev.
For more information about this sale or other intellectual property, please contact Joseph Popolo, IpAuctions, Inc. at 866-826-1300 or 348 Mill St., Reno, NV 89501 USA.
